Richard Dillon

Read the review by Brunangelo Falini and @DillonHaem. Criteria for diagnosis and molecular monitoring of #NPM1-mutated #AML. bit.ly/3QSHni9 @UniperugiaNews @kingsmedicine #acutemyeloidleukemia #leusm

@CarmeloGurnari @ASH_hematology @HematologyNews @NicoGagelmann Bravo!!

So happy to receive an ASH Abstract Achievement Award along with so many ASH friends from all over the world!!! ⁦@ASH_hematology⁩ ⁦@HematologyNews⁩ ⁦@NicoGagelmann⁩ 2023 - Hematology.org hematology.org/awards/award-r…

Dream Job Opportunity ! Academic Clinical Fellowship in Haematology (Guy's, King's, UCLH and Barts available) please contact me if interested in the Guy's / Kings one. oriel.nhs.uk/Web/PermaLink/…

@NicholasShortMD Love to if flight on time, send address :-)

For anyone planning to be in Houston for this year’s #SOHO2023 annual meeting, please join Dr Elias Jabbour and me on Tues 9/5 6-8pm for an educational dinner program discussing the prognostic and therapeutic importance of #MRD in #ALL. Please message me if interested!

Congratulations to our REBEL alliance @WillVilliers, @BoriMifsud, @DillonHaem, @halimabensmail, @AbduElbasir and our non-Twittered colleagues for an excellent collaboration.

Congratulations to @WillVilliers on his first born paper, i'm sure its the first of many.

Off to do some filming about what we can do RIGHT NOW to bring forward the day when no one dies of their blood cancer. @KingsCollegeLon & @GSTTnhs the location which is very apt given the vital role they both play in cancer discovery and treatment.

@gemmapeters Oh no i hope it wasn’t full of used coffee cups etc!!

Have turned ⁦@DillonHaem⁩’s office into a green room while he’s away - nice view Richard! Miss you!

Ultra sensitive detection of FLT3-ITD: a novel and powerful MRD marker - and one that could potentially be used to guide molecularly targeted interventions. Read all about it here! ashpublications.org/blood/article/…

@Tap_Clin_Trials This is wonderful news. We have come so far, so quickly, thanks to your support.

Exciting News - The VICTOR Trial has just opened its 30th #NHS site! @DillonHaem

Understanding the design of phase 3 trials in oncology 2000 2022

@CWLBloodDoc @Akld_DHB I think Auckland was in the top 3 recruiting centres in AML17 and also AML19 - thanks for the great, worldwide, and ongoing collaboration :-)

More high impact work from the NCRI AML trials. Glad that #Auckland #NZ can participate and contribute. #aml #leukemia @Akld_DHB

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia - Further results from the UK NCRI AML17 trial in collaboration with Australian colleagues. Hope you enjoy :-) sciencedirect.com/science/articl…

First patient recruited into Victor study @CV_UHB @DillonHaem @Tap_Clin_Trials , fantastic support again from the study team 👍👍

@CRGHaem @CV_UHB @Tap_Clin_Trials Amazing !!!! 🤩

We would like to thank all the speakers who joined us for a serie of seminars : @tobiasmenne2 @AKienesberger @MosheMittelman @manosnikolousis @DrAmitPatel @DillonHaem - All recordings are now available here: acuteleuk.org/upcoming-semin…

Had to wait for a long train ride to fully listen to this truly unmissable interview One great quote, among many: “The biggest tragedy is not that our drugs don’t work very well - though that’s a tragedy. The biggest tragedy is that we don’t know who they’re gonna work in.”

RECOVERY Pre-print: In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion: - reduced mortality - increased speed of discharge - reduced progression to invasive mechanical ventilation or death medrxiv.org/content/10.110…

Because our supporters were determined to keep donating & fundraising through the pandemic we were able to fund £2m of new research last month including @DillonHaem's team investigating if #AML can be treated without chemotherapy. #amazing 👇 bloodcancer.org.uk/research/resea…